Nancy Phelan, Wyeth
S
Nancy Phelan
ED, Consumer Communications and E-marketing, Wyeth
MOST RECENT HIT: Launched birth control pill Lybrel
ADDED VALUE: "Best Practices" brainiac
I saw firsthand the impact that disease can have on the person who has the disease, but also on the family," says Nancy Phelan. Her sister was often hospitalized with seer asthma, and not until Theo-Dur hit the market could she live a "normal" life. When it came to a career choice, Phelan chose pharma—Schering-Plough, the maker of Theo-Dur. After her field service, she rose fast into management, helping to take the allergy med Claritin over the counter. Winging it to Wyeth, she now helps with marketing strategy and best practices for all pharmaceutical brands. Phelan has a reputation for taking ethics as seriously as sales—a distinction for which she credits her industry mentors. "If you compromise once, you're going to compromise again," she says. As for her generation of new leaders, she says, "There does seem to be a new openness to new solutions, and an optimism that we can actually lead the change in healthcare, rather than only reacting once that happens."
Nancy Phelan
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
